GSK Puts Faith In Next Gen Respiratory, Real World Studies
Company Seeks Edge Over Rival AZ
Executive Summary
A pioneer in the field, can GSK’s investment in real world studies pay off?
You may also be interested in...
Blow To AZ As FDA Rejects COPD Contender
Issued with a complete response letter from the FDA, the company says it will now submit newer data showing the combination's effects on exacerbations.
AstraZeneca: Don’t Write Off Fasenra In COPD Just Yet
AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.